Amgen cancer drug panitumumab gets FDA priority review
LOS ANGELES (Reuters) – Biotechnology company Amgen Inc.
said on Monday that the U.S. Food and Drug Administration has
agreed to a “priority review” of the company’s application for
experimental drug panitumumab as a treatment for colon cancer.
With priority review status, the FDA will make its decision
on whether to approve the drug within six months, rather than
the usual 10- to 12-month review period.
The agency grants priority review to products that are
considered to be potentially significant therapeutic
advancements over existing therapies.